GLP1R and polycystic ovary syndrome: Dawson et al. demonstrated enhanced endothelial function and decreased serum triglycerides following EXE treatment [30], while Frossing et al. observed reductions in cardiovascular risk biomarkers, such as MR-proANP and MR-proADM, following LIRA therapy [32], further bolstering the cardiovascular advantages of GLP-1 RA administration for PCOS.